Rethinking how mobile units can catalyze progress on lung cancer screening: a scoping review of what we have learned.

Autor:	Karanth SD; Division of Population Health Sciences, Department of Surgery, University of Florida College of Medicine, Gainesville, FL, USA.; University of Florida Health Cancer Center, Gainesville, FL, USA., Divaker J; Division of Population Health Sciences, Department of Surgery, University of Florida College of Medicine, Gainesville, FL, USA., Blair M; Division of Population Health Sciences, Department of Surgery, University of Florida College of Medicine, Gainesville, FL, USA., Gray JE; Thoracic Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Hochhegger B; Department of Radiology, University of Florida College of Medicine, Gainesville, FL, USA., Kobetz E; Department of Public Health Sciences, University of Miami, Leonard M. Miller School of Medicine, Miami, FL, USA.; Sylvester Comprehensive Cancer Center, University of Miami, Leonard M. Miller School of Medicine, Miami, FL, USA., Machuca T; DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA., Rackauskas M; University of Florida Health Cancer Center, Gainesville, FL, USA., Yang D; Department of Epidemiology, University of Florida College of Public Health and Health Professions, Gainesville, FL, USA., Rodriguez E; Sylvester Comprehensive Cancer Center, University of Miami, Leonard M. Miller School of Medicine, Miami, FL, USA., Schabath MB; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Yoon HS; Division of Population Health Sciences, Department of Surgery, University of Florida College of Medicine, Gainesville, FL, USA.; University of Florida Health Cancer Center, Gainesville, FL, USA., Braithwaite D; Division of Population Health Sciences, Department of Surgery, University of Florida College of Medicine, Gainesville, FL, USA.; University of Florida Health Cancer Center, Gainesville, FL, USA.; Department of Epidemiology, University of Florida College of Public Health and Health Professions, Gainesville, FL, USA.
Jazyk:	angličtina
Zdroj:	Journal of thoracic disease [J Thorac Dis] 2024 Oct 31; Vol. 16 (10), pp. 7143-7154. Date of Electronic Publication: 2024 Oct 30.
DOI:	10.21037/jtd-24-846
Abstrakt:	Background: Despite United States Preventive Services Task Force (USPSTF) recommendations, low uptake of lung cancer screening (LCS) highlights the need for measures to promote adoption. This scoping review aims to outline the global landscape of mobile low-dose computed tomography (LDCT) platforms, summarizing research and evaluating efficacy in screening at-risk populations. Methods: We comprehensively searched Cumulative Index to Nursing and Allied Health Literature (CINAHL), PubMed, Embase, Scopus, and Web of Science for articles published between 2017 and 2023. Selected studies focused on mobile LCS programs using LDCT, providing details on program location, design, sample size, age, targeted population, lung cancer detection rate, and outcomes. Only studies meeting these criteria were considered. Results: The search found 12 studies meeting inclusion criteria, documenting ten mobile LDCT platforms across several countries. These studies primarily evaluated platform effectiveness in screening populations at risk, particularly targeting individuals who have ever smoked, high-risk individuals, and underserved populations. Two studies compared outcomes between mobile and hospital-based screening, while 10 other studies reported outcomes from mobile LDCT platforms. In US studies, most participants in mobile LCS programs came from rural areas, were uninsured or under-insured, and included a notable number of racial/ethnic minorities. The frequency of lung cancer diagnoses ranged from 0.33% to 3%, with the majority (80%) of detected at stages I and II. Conclusions: The mobile LDCT platforms emerge as a powerful solution to enhance access to LCS, especially for marginalized populations. By improving screening rates and enabling early detection, these platforms hold promise in narrowing healthcare disparities. Mobile LDCT presents a crucial opportunity to save lives and promote equity in healthcare access. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-846/coif). E.R. has received honoraria for CME Lectures from OncLive and Advisory Boards from Daiichi, Janseen/Johnson and Johnson, Astra Zeneca, Pfizer, Boehringer Ingelheim, and Oncohost, related to lung cancer treatment, but not lung cancer screening. J.E.G. has received honoraria and is board member for AbbVie; AstraZeneca; Blueprint Medicines; Coherus; Daiichi Sankyo; EMD Serono; Genentech; Gilead Sciences, Inc.; IDEOlogy Health; Janssen Scientific Affairs, LLC; Jazz Pharmaceuticals; Loxo Oncology Inc.; Merck & Co., Inc.; Novartis; OncoCyte Biotechnology; Regeneron; Spectrum ODAC; Takeda Pharmaceuticals; Triptych Health Partners; and Zai Lab (US) LLC. J.E.G. also has leadership or fiduciary roles, including ASCO Board of Directors Member, ASCO Education Committee Ex-Chair, IASLC Board of Directors Member and SWOG Lung Committee Chair and has received support for attending meetings and/or travel from AbbVie; OncoCyte; Spectrum Pharmaceuticals; and Coherus. J.E.G. has received grants/contracts from AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eli Lilly; EMD Serono-Merck KGaA; Genentech; Gilead Sciences: G1 Therapeutics; Ludwig Institute of Cancer Research; Merck & Co., Inc.; Novartis; Panbela Therapeutics; Pfizer; and Regeneron. JG has received consulting fees from AbbVie; AstraZeneca; Blueprint Medicines; Coherus; Daiichi Sankyo; EMD Serono; Genentech; Gilead Sciences, Inc.; IDEOlogy Health; Janssen Scientific Affairs, LLC; Jazz Pharmaceuticals; Loxo Oncology Inc; Merck & Co., Inc.; Novartis; OncoCyte Biotechnology; Regeneron; Spectrum ODAC; Takeda Pharmaceuticals; Triptych Health Partners; and Zai Lab (US) LLC. The other authors have no conflicts of interest to declare. (2024 AME Publishing Company. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu